

REMARKS

In the Restriction requirement mailed July 31, 2007, the Examiner divided the method claims of this application into the following five groups

Group I, claims 32-35, drawn to method of inhibiting TGF β ,

Group II, claims 36-37, drawn to method of reducing the accumulation of excess extracellular matrix,

Group III, claims 38-40, drawn to methods of treating a fibrotic condition,

Group IV, claims 41-42, drawn to method of inhibiting metastasis of tumor cells, and

Group V, claims 43-45, drawn to methods of treating a disease or disorder mediated by overexpression of TGF β .

Applicants elect Group I for prosecution. Applicants reserve the right to pursue the other, non-elected method claims in divisional applications.

Additionally, the Examiner alleges that the present "application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept" and requested the Applicants to elect "a single disclosed compound specie." Applicants provisionally elect for prosecution the single species 4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-pyrimidin-2-ylamine, which is specifically recited in claim 29 and shown below.

